Bristol Myers’ Growth Drugs Hit $7.7 Billion: Rapid Earnings Reaction

Bristol Myers Squibb's Growth Portfolio of newer drugs surged 12% to $7.7 billion in Q3 2026, driving the company's 7% overall revenue growth to $13.1 billion. While adjusted EPS fell 17% to $1.35, this decline reflects upfront acquisition costs for pipeline drugs rather than core business weakness. The company raised its 2026 revenue guidance to $49.75-$50.25 billion, signaling confidence in its drug portfolio diversification strategy.